Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 4
2014 1
2016 1
2018 5
2019 6
2020 9
2021 5
2022 6
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
CD26/DPP-4 in Chronic Myeloid Leukemia.
Sicuranza A, Raspadori D, Bocchia M. Sicuranza A, et al. Cancers (Basel). 2022 Feb 11;14(4):891. doi: 10.3390/cancers14040891. Cancers (Basel). 2022. PMID: 35205639 Free PMC article. Review.
Drug resistance and minimal residual disease in multiple myeloma.
Gozzetti A, Ciofini S, Sicuranza A, Pacelli P, Raspadori D, Cencini E, Tocci D, Bocchia M. Gozzetti A, et al. Among authors: sicuranza a. Cancer Drug Resist. 2022 Feb 16;5(1):171-183. doi: 10.20517/cdr.2021.116. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582527 Free PMC article. Review.
Peptide vaccines for hematological malignancies: a missed promise?
Bocchia M, Defina M, Aprile L, Sicuranza A. Bocchia M, et al. Among authors: sicuranza a. Int J Hematol. 2014 Feb;99(2):107-16. doi: 10.1007/s12185-013-1497-3. Epub 2014 Jan 8. Int J Hematol. 2014. PMID: 24399190 Free article. Review.
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, Pacelli P, Re F, Cavalleri A, Farina M, Malagola M, Russo D, De Fabritiis P, Bernardi S. Abruzzese E, et al. Among authors: sicuranza a. Cancers (Basel). 2023 Aug 15;15(16):4112. doi: 10.3390/cancers15164112. Cancers (Basel). 2023. PMID: 37627140 Free PMC article.
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.
Gandolfo C, Anichini G, Mugnaini M, Bocchia M, Terrosi C, Sicuranza A, Gori Savellini G, Gozzetti A, Franchi F, Cusi MG. Gandolfo C, et al. Among authors: sicuranza a. Vaccines (Basel). 2022 Jan 22;10(2):171. doi: 10.3390/vaccines10020171. Vaccines (Basel). 2022. PMID: 35214630 Free PMC article.
41 results